Skip To Main Content
Yingjun H Shang on Muck Rack

Yingjun H Shang

As seen in: Wiley Online Library, BioRxiv
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Yingjun H

Contact Yingjun H, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Vaccine‐Induced and Hybrid Immunity Against SARS‐CoV‐2 Variants of Concern in Two Cohorts in Queensland, Australia (2021-2022)

|
By Rhys Parry, Molecular Biosciences, Yingjun H Shang, Naphak Modhiran
| Wiley Online Library Verified
Conflicts of Interest The authors declare no conflicts of interest. References 1, , , et al., “Serology Characteristics of SARS-CoV-2 Infection After Exposure and Post-Symptom Onset,” European Respiratory Journal 56 (2020): 2000763, https://doi.org/10.1183/13993003.00763-2020. 2, , and , “The First 12 Months of COVID-19: A Timeline of Immunological Insights,” Nature Reviews Immunology 21 (2021): 245–256, https://doi.org/10.1038/s41577-021-00522-1.
Open in Who Shared Issue with article?

Vaccine-induced and hybrid immunity against SARS-CoV-2 variants of concern in two cohorts in Queensland, Australia (2021-2022).

|
By Rhys Parry, Julian Sng, Naphak Modhiran, Yingjun H Shang
| BioRxiv
Abstract The spike glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the main target for vaccine development, as antibodies generated against the spike protein are the most immunodominant and neutralizing against the virus. However, variants of concern (VOC), often containing multiple mutations within neutralizing epitopes, confer immune evasion of the response generated by current SARS-CoV-2 vaccines.
Open in Who Shared Issue with article?
See all 2 articles